Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
ACT [NYSE]
Actavis plc
IndexS&P 500 P/E- EPS (ttm)-4.18 Insider Own0.10% Shs Outstand265.06M Perf Week2.47%
Market Cap70.34B Forward P/E15.98 EPS next Y16.61 Insider Trans-0.04% Shs Float264.12M Perf Month-0.24%
Income-1046.00M PEG- EPS next Q3.49 Inst Own88.50% Short Float4.63% Perf Quarter12.63%
Sales11.78B P/S5.97 EPS this Y-793.40% Inst Trans31.39% Short Ratio3.94 Perf Half Y19.90%
Book/sh110.26 P/B2.41 EPS next Y22.48% ROA-3.10% Target Price302.67 Perf Year60.56%
Cash/sh1.28 P/C206.65 EPS next 5Y21.18% ROE-6.60% 52W Range161.92 - 272.75 Perf YTD57.97%
Dividend- P/FCF41.71 EPS past 5Y-35.20% ROI-3.00% 52W High-2.70% Beta0.34
Dividend %- Quick Ratio0.80 Sales past 5Y27.90% Gross Margin49.60% 52W Low63.90% ATR6.48
Employees19200 Current Ratio1.40 Sales Q/Q83.00% Oper. Margin-0.20% RSI (14)57.98 Volatility2.40% 2.06%
OptionableYes Debt/Eq0.53 EPS Q/Q-906.10% Profit Margin-8.10% Rel Volume1.14 Prev Close263.75
ShortableYes LT Debt/Eq0.52 EarningsNov 05 BMO Payout- Avg Volume3.10M Price265.39
Recom1.60 SMA200.57% SMA506.40% SMA20018.31% Volume3,526,396 Change0.62%
Nov-21-14Reiterated Argus Buy $285 → $310
Nov-20-14Reiterated RBC Capital Mkts Top Pick $291 → $323
Nov-18-14Reiterated UBS Buy $278 → $333
Nov-06-14Reiterated RBC Capital Mkts Top Pick $286 → $291
Sep-22-14Downgrade Barclays Overweight → Equal Weight $250 → $250
Aug-06-14Reiterated UBS Buy $237 → $254
Jul-02-14Reiterated CRT Capital Buy $245 → $275
Jun-27-14Initiated Canaccord Genuity Buy $275
May-12-14Upgrade RBC Capital Mkts Outperform → Top Pick $252 → $259
May-01-14Reiterated CRT Capital Buy $230 → $245
Apr-28-14Reiterated National Alliance Securities Buy $246 → $259
Apr-17-14Initiated National Alliance Securities Buy $246
Feb-21-14Reiterated RBC Capital Mkts Outperform $240 → $249
Feb-19-14Reiterated UBS Buy $202 → $237
Feb-19-14Reiterated CRT Capital Buy $210 → $230
Feb-19-14Reiterated Barclays Overweight $230 → $250
Feb-03-14Reiterated RBC Capital Mkts Outperform $202 → $222
Feb-03-14Reiterated Barclays Overweight $190 → $230
Jan-17-14Reiterated Argus Buy $180 → $198
Jan-07-14Initiated RBC Capital Mkts Outperform $202
Dec-19-14 04:15PM  XYDALBA (dalbavancin) Receives CHMP Positive Opinion for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Adults PR Newswire
09:00AM  Actavis to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference PR Newswire
Dec-18-14 06:09PM  Baidu, Alibaba Among Top World Stocks Building Bases at Investor's Business Daily
11:54AM  Tetraphase Jumps As 'Superbug' Drug Scores In Trial at Investor's Business Daily
Dec-16-14 10:12PM  Few Allergan execs to keep top jobs in Actavis takeover at Los Angeles Times
06:11PM  Great Stocks: Valeant Pharmaceuticals Near Buy Point at Investor's Business Daily
10:28AM  Actavis Unveils Management Changes at The Wall Street Journal
10:11AM  Pharma Deal's Victor Now Must Execute at The Wall Street Journal
09:49AM  Activis to Replace Most Allergan Executives After Deal at Bloomberg
09:42AM  FDA Ruling Blocking Celebrex Generics Reversed in Win For Mylan at Bloomberg
07:30AM  Actavis Announces Proposed Senior Leadership Team Effective Following Completion of Allergan Acquisition PR Newswire
07:06AM  Court Rules on Alzheimers Drug at The Wall Street Journal
07:06AM  Pharma Deals Victor Now Must Execute at The Wall Street Journal
Dec-15-14 06:47PM  Judge halts Alzheimer's drug swap until July AP
03:10PM  Actavis Will Appeal Injunction Requiring Continued Distribution of NAMENDA┬« IR PR Newswire
09:27AM  Buffett and Billionaire Investors Look to Oil, Health Care and Spinoffs in 2015 at TheStreet
Dec-12-14 05:10PM  ACTAVIS PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
02:20PM  Actavis Likely to Continue Selling Namenda IR Tablets Zacks
12:00PM  Chilton starts new position in Medtronic Market Realist
08:00AM  Chilton initiates new position in Actavis Market Realist
Dec-11-14 07:54PM  Actavis Loses Ruling on Immediate-Release Alzheimers Drug at Bloomberg
07:14PM  U.S. judge says Actavis must keep selling Alzheimer drug Reuters
06:52PM  Actavis Confirms District Court Ruling to Require Continued Distribution of NAMENDA IR PR Newswire
06:15PM  U.S. judge rules Actavis must continue to sell Alzheimer's drug Reuters
03:45PM  bluebird bio (BLUE) Soars on Data from LentiGlobin Study Zacks
Dec-10-14 10:35AM  What a Generic Celebrex Means for Pfizer and for Actavis at 24/7 Wall St.
09:28AM  Actavis Launches Generic Version of Celebrex┬« PR Newswire
Dec-09-14 11:55AM  Stock Market Today: Wall Street Drops; Conn's Down 40% at Investor's Business Daily
Dec-08-14 06:39PM  Top Global Stocks: Jazz, Actavis In IBD's World List at Investor's Business Daily
05:30PM  Actavis' Antibiotic Backed for FDA Approval, Response in Q1 Zacks
11:48AM  Merck Acquiring Cubist, Focusing On Hospital Care at Investor's Business Daily
Dec-07-14 04:27PM  Reports: Merck in talks to buy Cubist at USA TODAY
Dec-05-14 07:25PM  FDA panel recommends approval for Actavis' antibiotic drug Reuters
05:03PM  ACTAVIS PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
04:46PM  Anti-Infective Advisory Committee Recommends Approval Of Actavis' Ceftazidime-Avibactam PR Newswire
12:48PM  Activist Investors Torn on Private Equity Partnerships at TheStreet
09:17AM  Goldman's Parker Calls Allergan Pursuit a 'One-time Opportunity' at TheStreet
Dec-04-14 06:20PM  Great Stocks: Mallinckrodt Buys Raise Profit Margins at Investor's Business Daily
Dec-02-14 06:19PM  U.S. Stock Mutual Funds Led Advance In November at Investor's Business Daily
05:45PM  Actavis Launches Generic of Shire's ADHD Drug Intuniv Zacks
Dec-01-14 04:05PM  Actavis Launches Generic Version of Intuniv┬« PR Newswire
Nov-26-14 08:59AM  Ackman's Pershing Square still holds 26.6 million Allergan shares Reuters
05:59AM  Why Actavis (ACT) Could Be an Impressive Growth Stock Zacks
Nov-25-14 06:35PM  5 Ways CEOs Handle Activist Investors at The Wall Street Journal
05:20PM  Quick Look at the Lg Cap All Time Highs... Yahoo Finance Blogs
07:00AM  Let's Make a Deal: The Outlook for Merger Funds Morningstar
Nov-24-14 06:49PM  Actavis mulls job cuts, China expansion: Bloomberg Reuters
06:46PM  Actavis mulls job cuts, China expansion - Bloomberg Reuters
05:36PM  Give Thanks? S&P 500, Dow Industrials Hit New Highs, While Nasdaq, Small Caps Surge at Barrons.com
04:18PM  Taking Stock: McCracken on Smith & Nephew Deal Coming Back at Bloomberg
12:48PM  Actavis Plans Job Cuts, China Expansion for Allergan at Bloomberg
10:54AM  Hedge funds playing buy-and-hold, and losing at CNBC
08:14AM  US STOCKS-Futures rise, boosted by merger activity Reuters
Nov-22-14 02:07PM  PPG Is Spot-On; The Hazards of Skepticism: Jim Cramer's Best Blogs TheStreet
Nov-21-14 11:15PM  Review at Barrons.com
03:49PM  Podcast: Do Allergan, Actavis, and Ackman Hint at a Market Top? at The Wall Street Journal
12:23PM  If You Don't Own Apple, Actavis and Alibaba, Go Back To Sleep at Forbes
08:26AM  Allergan deal sits well on Actavis chief's 'Monopoly board' at Financial Times
04:11AM  After losing out over Allergan, Valeant announces $2 billion buyback at Fortune
Nov-20-14 03:34PM  Synergy Pharmaceuticals Drug Fares Well in Phase II Study Zacks
12:13PM  [$$] Valeant Sets $2 Billion Buyback Plan at The Wall Street Journal
Nov-19-14 05:35PM  Mallinckrodt Q4 Earnings Beat Views, But Outlook Hazy at Investor's Business Daily
04:10PM  Celgene Up on Encouraging Long-Term Phase III Otezla Data Zacks
11:42AM  Mallinckrodt Earnings Beat But No New Guidance at Investor's Business Daily
10:26AM  US stocks retreat from records before Fed release at CNBC
08:37AM  Allergan's Price Tag Gets Even Richer at The Wall Street Journal
07:58AM  The Zacks Analyst Blog Highlights: Actavis, Allergan, iShares U.S. Pharmaceuticals ETF, Market Vectors Pharmaceutical ETF and SPDR S&P Pharmaceuticals ETF Zacks
Nov-18-14 06:26PM  Stocks rally: Dow, S&P 500 set closing highs at USA TODAY +8.74%
06:15PM  [$$] Jack Lew, Irish Hero at The Wall Street Journal
06:00PM  Cramer shares hazards of skepticism CNBC
05:04PM  Vipshop, Jack in the Box Rise In After-Hours Trading at Investor's Business Daily
04:35PM  S&P, Dow ring up records Tuesday at MarketWatch
03:16PM  PetSmart, Jack in the Box earnings in focus after hours at MarketWatch
03:15PM  Zoetis 2015 Guidance Misses As Buyout Theories Abound at Investor's Business Daily
03:02PM  Actavis: One Day Later, Investors Really Like Allergan Acquisition at Barrons.com
02:58PM  [$$] Actavis-Allergan Deal Friendly to Shareholders at Barrons.com
02:38PM  Stock Movers: Why 4 Big Drug Stocks Are Rising Today at Investor's Business Daily
01:53PM  Deals Heat Up for Lawyers Like Its 1998 Bloomberg
01:38PM  Ackman supports Allergan's $66 billion sale to Actavis Reuters
01:35PM  ZOETIS SHARES ARE HALTED Business Insider
01:33PM  Stocks Hold Near Fresh Milestones; Actavis Hits New High at Investor's Business Daily
01:10PM  Ackman Pledges Support For Actavis Bid On Allergan Benzinga
12:30PM  Actavis shares outpace buyout targets gains at MarketWatch
12:20PM  Actavis Strikes $66 Billion Deal for Botox Maker Allergan Zacks
12:08PM  Ackman withdraws special Allergan meeting CNBC
11:47AM  Jim Cramer: Which Stocks Stand Out as Winners? Here's My List at TheStreet
11:45AM  Ackman says supports Allergan's $66 billion sale to Actavis: CNBC Reuters
11:43AM  Ackman says supports Allergan's $66 billion sale to Actavis -CNBC Reuters
11:29AM  Dealpolitik: Praise for Allergan Directors, Not Pershing Square at The Wall Street Journal
11:14AM  Actavis (ACT) Is Today's Unusual Social Activity Stock at TheStreet
11:06AM  One Factor Driving Up Actavis (ACT) Stock Today at TheStreet
10:33AM  Stocks Most Loved By Hedge Funds at Barrons.com
10:27AM  Ackman to CNBC: Support Actavis-Allergan deal CNBC
09:10AM  Cramer: Waiting for Santa Claus rally CNBC
09:03AM  [$$] Actavis Outlines Allergan Breakup Fee at The Wall Street Journal
08:51AM  Cramer's stocks to watch: AAPL, AGN & HD CNBC
08:44AM  Citi Raises Price Target On Actavis Benzinga
08:11AM  ACTAVIS PLC Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Financial Statements and Exhibits EDGAR Online
06:26AM  Zacks Investment Ideas feature highlights: Allergan, Actavis, Sketchers and Zeltiq Aesthetics Zacks
06:08AM  Actavis' dealmaking builds drug powerhouse at Financial Times
Actavis plc, an integrated specialty pharmaceutical company, is engaged in the development, manufacture, marketing, sale, and distribution of pharmaceutical products in the Americas, Europe, the Middle East, Africa, Australia, and the Asia Pacific. It operates in three segments: Actavis Pharma, Actavis Specialty Brands, and Anda Distribution. The Actavis Pharma segment provides generic, branded generic, and over-the-counter (OTC) pharmaceutical products. This segment sells generic prescription products primarily under the Watson Laboratories, Watson Pharma, and Actavis Pharma labels; and OTC generic products under private label. The Actavis Specialty Brands segment offers patent-protected products and trademarked off-patent products, which are marketed as branded pharmaceutical products to physicians, specifically urologists, obstetricians, dermatologists, gastroenterologists, and gynecologists. The Anda Distribution segment primarily distributes generic and selected brand pharmaceutical products, vaccines, injectables, and OTC medicines to independent pharmacies, and to alternate care providers comprising hospitals, nursing homes, and mail order pharmacies, as well as to pharmacy chains, physicians' offices, and buying groups. The company also develops and out-licenses generic pharmaceutical products primarily in Europe through its third-party business; and provides products in women's health, urology, gastroenterology, and dermatology therapeutic categories. The company has a collaboration agreement with Amgen, Inc. for the development and commercialization of various oncology antibody biosimilar medicines; and a collaboration agreement with Hanmi Pharm. Co. Ltd. to develop Hyalrheuma, a hyaluronic acid injection for arthritis pain treatment. Actavis plc was founded in 1983 and is headquartered in Parsippany, New Jersey.